Current Trials of the German Adjuvant Breast Cancer Group (GABG)

  • M. Kaufmann
Conference paper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 152)

Abstract

Objectives of currently active randomised trials of the GABG in women with primary breast cancer are:
  1. 1.

    Risk-oriented selection of patients by tumor size, menopausal status, nodal involvement and hormonal receptor content

     
  2. 2.

    Chemo-endocrine or endocrine-endocrine sequences in pre- and post-me-nopausal patients

     
  3. 3.

    Chemo- or endocrine therapy in pre-menopausal patients

     
  4. 4.

    Reduction of local treatment (axillary surgery, radiotherapy)

     
  5. 5.

    Preoperative chemotherapy in operable breast cancer.

     

Keywords

Breast Cancer Metastatic Breast Cancer Preoperative Chemotherapy Operable Breast Cancer Premenopausal Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bonadonna G (1992) Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 52:2127–2137PubMedGoogle Scholar
  2. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartolo C, deYoldi G, Zucali R, Rilke F, Andreola S, Silvestrini R, DiFronzo G, Valgussa P (1990) Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82:1539–1541PubMedCrossRefGoogle Scholar
  3. Bonadonna G, Valagussa P, Brambilla C (1991) Adjuvant and primary treatment of breast cancer with chemotherapy and/or endocrine therapy. Semin Oncol 18:515PubMedGoogle Scholar
  4. Bourgeois H, Gruia G, Dieras V, Kalla S, Giaccetti S, Cvitkovic E, Aussei JP, Azli N, Riva A, Pouillart P, Misset JL (1996) Docetaxel in combination with doxorubicin as 1st line CT of metastatic breast cancer (MBC): a phase I dose finding study. Proc Am Soc Clin Oncol 15:148Google Scholar
  5. Chan S, Friedrichs K, Noel D, Duarte R et al (1997) A randomized phase III study of Taxo-tere (T) versus doxorubicin (D) in patients (pts) with metastatic breast cancer (MBC) who have failed an alkylating containing regimen: preliminary results. Proc Am Soc Clin Oncol 16:540Google Scholar
  6. Feldmann L, Hortobagyi G, Buzdar A, Ames F, Blumenstein GR (1986) Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46:2578–2581Google Scholar
  7. Fisher B, Brown A, Mamounas E, Wieland S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolkmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on local-egional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483–2493PubMedGoogle Scholar
  8. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, Hug V, Hohnes FA, Romsdahl MM, Fraschini G, McBride CM, Martin RG, Montague E (1988) Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62:2507–2516PubMedCrossRefGoogle Scholar
  9. Kalla S, Bourgeois H, Gruia G, Dieras V, Giacchetti S, Cvitkovic E, Aussei JP, Azli N, Riva A, Pouillart P, Misset JL (1996) Docetaxel in combination with doxorubicin as first line chemotherapy of metastatic breast cancer: a phase I dose finding study. Final results. Ann Oncol 7 Suppl 5:124–125Google Scholar
  10. Kaufmann M, Jonat W, Abel U, Hilfrich J, Caffier H, Kreienberg R, Trams G, Brunnert K, Schermann J, Kleine W et al (1993) Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer. J Clin Oncol 11(3):454–460PubMedGoogle Scholar
  11. Scholl SM, Fouquet A, Asselain B, Pierga JA, Vilcoq JR, Durand JC, Dorval T, Palangie T, Jouve M, Beuzeboc P (1994) Primary versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A(5):645–652PubMedCrossRefGoogle Scholar
  12. Schumacher M, Bastert G, Bojar H, Hubner K, Olschewski M, Sauerbrei W, Schmoor C, Beyerle C, Neumann RL, Rauschecker HF (1994) Randomized 2x2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study Group. J Clin Oncol 12(10):2086–2093PubMedGoogle Scholar
  13. Surbone A, Norton L (1993) Kinetic concepts in the treatment of breast cancer. Ann NY Acad Sci 698Google Scholar
  14. Von Minckwitz G, Costa SD (1997) Docetaxel (Taxotere/-E) zur Therapie des Mammakarzi-noms — Höchste Wirksamkeit bei moderaten Nebenwirkungen. Med Klin 92 Suppl 4:4–9CrossRefGoogle Scholar
  15. Von Minckwitz G, Kaufmann M, Schmid H, Kleine W, Brunnert K, Ulmer MU, Stosiek U, Mahlke M, Mehrpohl HG, Neises M, Baltzer J (1995) Tamoxifen in patients with node-negative and receptor-positive breast cancer: the Heidelberg II and GABG II experience. 5th International Conference on Adjuvant Therapy of Primary Breast Cancer, St. Gallen, Abstract book, p 80Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1998

Authors and Affiliations

  • M. Kaufmann
    • 1
  1. 1.University Women’s HospitalFrankfurt am MainGermany

Personalised recommendations